Literature DB >> 15796188

Novel camptothecin derivatives.

Kathleen Legarza1, Li-Xi Yang.   

Abstract

Efforts continue to be made in the field of oncology to find new and effective chemotherapeutic agents against cancer. From these efforts the camptothecins have emerged as a promising group of agents. Camptothecin, first discovered in 1958, was found to be an effective anti-chemotherapeutic agent, but the toxicities were too great to be used in a clinical setting. Derivatives of the original camptothecin molecule have been created by modifying one or more rings in an effort to improve the pharmacokinetics and toxicity profiles of the parent compound. This article reviews both the in vivo and in vitro characteristics of these novel agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15796188

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  3 in total

Review 1.  Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Authors:  Fengzhi Li; Tao Jiang; Qingyong Li; Xiang Ling
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

2.  Dual action of NSC606985 on cell growth and apoptosis mediated through PKCδ in prostatic cancer cells.

Authors:  Xin Wang; Chen Tan; Guo Wang; Jing-Jing Cai; Li-Ping Wang; Julianne Imperato-McGinley; Yuan-Shan Zhu
Journal:  Int J Oncol       Date:  2017-09-27       Impact factor: 5.650

3.  A novel approach for organelle-specific DNA damage targeting reveals different susceptibility of mitochondrial DNA to the anticancer drugs camptothecin and topotecan.

Authors:  M C Díaz de la Loza; R E Wellinger
Journal:  Nucleic Acids Res       Date:  2009-01-16       Impact factor: 16.971

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.